CAS 1215197-37-7

(S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid

CAS: 1215197-37-7

(S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid

Purity: 99%

Molecular weight: 396.37g/mol

Ref: 54-PC1006424

PF-04991532

CAS: 1215197-37-7

PF-04991532 is a hepatoselective glucokinase activator that reduces plasma glucose and AMP concentrations in the Goto-Kakizaki rat model.

Formula: C₁₈H₁₉F₃N₄O₃

Purity: 99.99%

Color and Shape: Solid

Molecular weight: 396.36

Ref: TM-T16480

PF 04991532

Controlled Product

CAS: 1215197-37-7

Formula: C₁₈H₁₉F₃N₄O₃

Color and Shape: Neat

Molecular weight: 396.364

Ref: TR-P294123

PF 04991532

CAS: 1215197-37-7

PF 04991532 is a cyclopentyl compound that has been shown to have antiviral activity against HIV-1 and hepatitis C virus (HCV) in vitro. It also inhibits the production of inflammatory cytokines such as TNF-α and IL-6, and prevents HCV infection by blocking the interaction of Toll-like receptor 4 with its ligand. PF 04991532 also has an effect on axonal growth in rats with hepatic steatosis. PF 04991532 is administered orally, at a dose of 10 mg/kg once daily for 28 days. This treatment was found to be safe and well tolerated. There were no significant changes in pharmacokinetic parameters between the treatment group and the placebo group. The drug is not metabolized by cytochrome P450 enzymes, but it undergoes glucuronidation after being metabolized by other enzymes, resulting in a glucuronide conjugate (PF04991532-G).

Formula: C₁₈H₁₉F₃N₄O₃

Purity: Min. 95%

Molecular weight: 396.36 g/mol

Ref: 3D-BP168016